Not everyone can access twitter content if they don’t have an account only the first tweet in a thread can be seen - what was the response you’re referring to?
I’m sorry about that. Full response below -
‘Thank you for your email from 12 May on behalf of the “Not Recovered UK” long COVID and ME/CFS patient community. I apologise for the delay in response, which was due to
correspondence rules around the General Election.
I would like to reassure you that we are committed to taking a comprehensive and
compassionate approach to supporting individuals with ME/CFS and long COVID,
recognising the unique challenges they present. The Government is aware that ME/CFS and long COVID can have a devastating effect on those who suffer from them and recognises that they are under-researched areas. With this in mind, I would like to update you on recent activities in this area.
DHSC published ‘My Full Reality’, an interim Delivery Plan for ME/CFS in August 2023,
which sets out a number of actions to improve the experiences and outcomes for people with
ME/CFS through an expansion of research, better education of professionals, improvements in attitudes towards the condition and improvements to service provision.
Supported by DHSC, the UK Clinical Research Collaboration (UKCRC) convened a Research Working
Group to explore the barriers facing researchers in this area. This group has met regularly for two years and outputs include the development of the research chapter of the interim Delivery Plan, commissioning an evidence synthesis map of ME/CFS research, as well as a number of ongoing workshops on ME/CFS research.
Alongside the publication of the interim Delivery Plan, we ran a public consultation to gather the views and experiences of healthcare professionals, organisations and individuals with lived experiences of ME/CFS.
The aim of the consultation is to build a picture of how well the interim delivery plan identifies and meets the needs of the ME/CFS community, and to understand where there are any gaps where further action may be necessary. The consultation received well over 3,000 highly detailed responses, which are in the process of being analysed. Publication of the response to the consultation and a final delivery plan are questions for the incoming government.
You have highlighted important points about the UK research landscape for ME/CFS and
long COVID. The National Institute for Health and Care Research (NIHR) and Medical
Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences and treatment of ME/CFS and are actively exploring next steps for ME/CFS and long COVID research.
We recognise that in ME/CFS and long COVID research there are particular challenges
preventing scientific progress and are working with other relevant funders to develop
strategic solutions. The NIHR has worked closely with the MRC on ME/CFS and long Covid research for this reason, and we will continue to do so.
The NIHR welcomes fundingapplications for research into any aspect of human health including ME/CFS and long COVID. These applications are subject to peer review and judged in open competition, with
awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.
Unfortunately, despite our efforts to
stimulate high quality research in this area, we have received a low number of applications in
this space. We will continue to work with the community, including yourselves, to identify
new solutions to increase research in this area.
But we have made some progress. As you are aware, through the NIHR, DHSC has co-
funded, with the MRC the £3.2m DecodeME study into the genetic underpinning of ME/CFS.
The study will analyse samples from 25,000 people with ME/CFS to search for genetic
differences that may indicate underlying causes or an increased risk of developing the
condition. This study aims to increase our understanding of the disease and therefore
contribute to the research base on diagnostic tests and targeted treatments for
ME/CFS. We hope that DecodeME will empower future research by revealing genetic risk
factors and facilitating future studies through the provision of an open-source data and
sample base.
For long COVID research, we have invested over £50 million through two specific research
calls, co-funded with UK Research and Innovation (UKRI). The projects funded aim to improve our understanding of the diagnosis and underlying mechanisms of the disease and the effectiveness of both pharmacological and non-pharmacological therapies and
interventions, as well as to evaluate clinical care. The NHS and scientific community are
working at pace to progress long COVID research, including for children and young
people. As findings emerge from current research, we encourage researchers to apply forfunding to build on and develop the newly established infrastructure, partnerships, and
research capabilities. Government research funders remain available to support long COVID
researchers in their applications for funding.
As you know so well, long COVID is a complex multi-system disease and may in fact
comprise a number of syndromes with different underlying mechanisms. While there is no
single treatment for long COVID, there are treatments available to help manage some of the
symptoms.
We have funded clinical trials to test and compare different treatments such as
antihistamines, anticoagulants and anti-inflammatory medicines, as well as trials such as
REGAIN, which combine exercise with behavioural support, to measure their effects on
symptoms, health and other outcomes. Specifically, the REGAIN trial is the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high quality evidence confirming the sustained clinical benefit and lack of harm with rehabilitation programmes for long COVID. In this trial, practitioners were also appropriately trained in risks relating to post-exertional malaise. Many clinical trials are underway both in the UK and
internationally.
Finally, we have both been encouraged by emerging findings of potential mechanisms
underpinning long COVID, offering potential future pathways to therapeutic options for these patients and we hope to see new insights on ME/CFS emerging from the DecodeME programme in the near future. While ME/CFS and long COVID should not be seen as synonymous, the opportunity for scientific synergy is clear.
I hope that this response provides reassurance that we take seriously the challenge of ME/CFS and long COVID and are committed to ensuring that those living with it have the opportunity to participate in and benefit from research, with the aim of improving outcomes.
Yours sincerely,’